Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Bayer Q2 misses forecasts as costs, forex effects bite

Stock MarketsAug 05, 2021 06:21AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The logo of Bayer AG is seen in a showroom of the German drugmaker where the annual results news conference takes place in Leverkusen, Germany February 27, 2020. REUTERS/Wolfgang Rattay/File Photo

By Christoph Steitz

FRANKFURT (Reuters) - Bayer (OTC:BAYRY) shares fell to their lowest levels in more than seven months after the German agricultural and pharmaceuticals group reported lower-than-expected second-quarter core earnings due to higher production costs and currency headwinds.

Second-quarter earnings before interest, tax, depreciation and amortisation (EBITDA) before special items fell 10.6% to 2.58 billion euros ($3.05 billion), missing the 2.79 billion forecast analysts had expected on average.

Shares in the group fell by as much as 6.1% to the bottom of the DAX, hitting their lowest since Dec. 21, 2020, after second-quarter adjusted EBITDA at Bayer's Crop Science division declined by more than a quarter.

"Higher prices and volumes, along with contributions from ongoing efficiency programmes only partly offset an increase in costs," Bayer said in a statement.

Barclays (LON:BARC) analysts said investors might be concerned by the impact of cost inflation at the Crop Science division, which includes the Roundup weedkiller brand Bayer acquired as part of the $63 billion takeover of Monsanto (NYSE:MON).

The decline in core earnings overshadowed Bayer's lifted full-year outlook, following stronger sales of prescription medicines that recovered from restrictions related to the COVID-19 pandemic.

Bayer expects sales of 43 billion euros this year, up from 41 billion earlier. EBITDA before special items is seen at 10.6 billion to 10.9 billion euros, compared with 10.5 billion to 10.8 billion previously.

The more optimistic outlook was partly driven by Bayer's pharmaceuticals division, where second-quarter sales rose 16.2% and which is being strengthened by the acquisition of Vividion Therapeutics for up to $2 billion.

"Vividion's unique technologies and special expertise will significantly strengthen our drug discovery capabilities," Bayer Chief Executive Werner Baumann said in a statement.

Bayer last week said it would book additional provisions of $4.5 billion related to litigation, which alleges that Roundup can cause cancer, bringing the total to $16.1 billion.

Bayer said it would file in August a petition with the U.S. Supreme Court seeking a review of a lower court ruling that went in favour of Roundup user Edwin Hardeman.

($1 = 0.8451 euros)

Bayer Q2 misses forecasts as costs, forex effects bite
 

Related Articles

Silver Sentiment Hits Worst Level in Years
Silver Sentiment Hits Worst Level in Years By StockNews - Sep 23, 2021

Silver (SLV) is down 5% this month and re-testing the $22.50/oz level. This relentless selling pressure continues to put a massive dent in sentiment, with despondency across the...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email